Nanobiotix Provides First Quarter 2026 Operational and Financial Update
Nanobiotix announced positive operational progress and financial updates for Q1 2026. The company successfully completed a 9.1 million follow-on offering, strengthening its financial position to fund operations into 2029. Newly presented Phase 2 data for JNJ-1900 (NBTXR3), a novel nanotherapy for Stage 3 inoperable NSCLC, showed encouraging respon…